Tekla Life Sciences Investors

NYSE:HQL

Asset Management

Financial Services
$19.27 +0.62%

+$0.11 today

Market cap
$585.96M
Beta
0.73
P/E (TTM)
2.8
EPS (TTM)
$6.52
Dividend yield
11.35%
52W Low $12.34High $18.46

Volume 0.12M

Average 0.11M

HQL Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Tekla Life Sciences InvestorsNYSE: HQL

Net Receivables · Q2 FY2026 · quarter ended Mar 2026

Net receivables falls 80.0% from a year ago

Net receivables stood at $1.28M at the end of Q2 FY2026, down 80.0% from a year earlier. Over 3 fiscal years it compounded at +22.2% a year.

Context

  • Net receivables amounted to 0.2% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -80.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.28M— QoQ
Last fiscal yearSep 2025
$1.14M+392.5% YoY
Year agoMar 2025
$6.39M-80.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.0%——
1 year+392.5%——
3-year CAGR+22.2%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
1.14M USD
Year-over-year change
+392.5%
4-year CAGR
+65.9%

Net Receivables vs competitors

How HQL compares with its peers on the latest reported figures

  • HQL's Mar 2026 net receivables of $1.28M is the 8th highest of the 10 companies compared; the peer median is $6.82M.
  • Its year-over-year change of -80.0% is the 8th highest of 10, against a peer median of -12.2%.
  • Net receivables amounts to 0.2% of total assets for HQL, versus a peer median of 0.6%.
HQL Competitors Peer median
Net Receivables for HQL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PNNTPennantPark Investment CorporationMar 2026$4.66B +40752.9%-34.2%0.4%
ECCEagle Point Credit Company Inc.Dec 2025$49.3M -5.0%+11.1%3.5%
CCAPCrescent Capital BDC, Inc.Mar 2026$23.42M +176.7%—1.4%
TCPCBlackRock TCP Capital Corp.Mar 2026$21.13M -12.2%+0.9%1.4%
GAINGladstone Investment CorporationMar 2026$6.82M -28.5%-0.6%0.5%
GLADGladstone Capital CorporationMar 2026$5.65M +0.2%+20.9%0.6%
SORSource Capital, Inc.Dec 2025$2.37M -25.3%-5.8%0.6%
HQLTekla Life Sciences InvestorsMar 2026$1.28M -80.0%+22.2%0.2%
CIONCION Investment CorporationMar 2026$48K -99.9%-86.8%0.0%
MCIBarings Corporate InvestorsDec 2025$0 -100.0%—0.0%
Peer median (excluding HQL) $6.82M-12.2%-0.6%0.6%

Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents990445477175.54K
Short-term Investments0015.24M17.23M0
Net Receivables150.34K623.47K5.04M231.11K1.14M
Inventory00000
Other Current Assets(32.97K)(25.18K)08.97K0
Total Current Assets144.66K623.92K5.05M281.61K1.25M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments534.01M414.08M397.53M460.3M505.7M
Tax Assets00000
Other Non-current Assets534.01M414.7M402.57M13.9M514.13M
Total Non-current Assets534.01M414.08M397.53M474.2M514.13M
Total Assets534.19M414.73M402.6M460.58M515.38M
Account Payables150.34K5.1M01.79K720.9K
Short-term Debt10.04M11.09M000
Tax Payables00000
Deferred Revenue05.09M000
Other Current Liabilities(8M)(16.18M)050.81K0
Total Current Liabilities10.75M5.1M0888.61K720.9K
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities10.75M11.72M666.96K886.82K1.01M
Total Non-current Liabilities10.75M11.72M666.96K886.82K1.01M
Total Liabilities10.75M16.82M666.96K888.61K1.73M
Common Stock246.68K256.8K267.91K280.61K295.99K
Retained Earnings150.7M9.55M(1.48M)44.13M77.6M
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity523.44M397.9M401.93M459.69M513.66M
Total Debt1.34M11.09M000
Net Debt1.34M10.65K(477)(1)(75.54K)

Tekla Life Sciences Investors

NYSE:HQL

Intrinsic Alpha fair value

Locked

Current Price

$19.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.